

CONQUERING THORACIC CANCERS WORLDWIDE

# 2020

ANNUAL REPORT



INTERNATIONAL  
ASSOCIATION  
FOR THE STUDY  
OF LUNG CANCER

**CONNECT WITH US**

 @IASLC

 facebook.com/IASLC

 @iaslungcancer

 linkedin.com/IASLC

 IASLC

# TABLE OF CONTENTS

- 4 WELCOME LETTER
- 6 MEMBERSHIP
- 8 WEBSITE INTEGRATION
- 10 EDUCATION & CONFERENCES
- 12 WCLC 2020
- 14 SCIENTIFIC AFFAIRS
- 20 JTO AND JTO CRR
- 22 PATIENT ADVOCACY
- 26 WEBINARS
- 28 CORPORATE RELATIONS
- 30 INTERNATIONAL LUNG CANCER FOUNDATION
- 32 2020 DONORS
- 34 BOARD OF DIRECTORS AND STAFF



Dr. Walter Curran shares research insights at the 2020 Targeted Therapies of Lung Cancer Meeting.

# Bem vindo Karibu 환영 欢迎

## WELCOME

أهلاً  
Tervetuloa  
Bienvenido

Benvenuto

This year has been marked by opportunities, challenges, and change. It has compelled us to rethink time-tested approaches and norms while forcing us to adapt, learn new skills, and adjust our behaviors. The SARS-CoV-2 pandemic, or COVID-19, has touched every aspect of our lives, both personally and professionally. The IASLC has been impacted by the pandemic as well. It has affected our work—from member engagement, to education and meetings, to communications, scientific projects, our finances, and operations. Just as our members have risen to the challenge posed by this historic pandemic, whether through patient care or research, the IASLC has devoted itself to making the necessary adjustments caused by the pandemic while also preparing for the future.

Early in 2020, as the pandemic was taking hold, the IASLC Board of Directors and Leadership adopted a management approach to meet this moment. By leveraging the strengths and the 45-year history of the society, we vowed to maintain a long-term perspective when making decisions. We committed ourselves to producing relevant content offerings and value for our members and the field. We adjusted quickly to diversify how that content was delivered via new modalities and we continued to make the key investments as outlined in the organization's strategic plan. But most important was the continued health and safety of our members, stakeholders, partners, and staff.

These dynamics led us to reconsider how we delivered our 2020 meetings. In October, we held the IASLC 2020 Hot Topic: Liquid Biopsy Meeting and the 2020 North America Conference on Lung Cancer Meeting in virtual formats. IASLC faculty presented the advances in liquid biopsy technology and shared lively discussions on clinical applications. More than 450 individuals from over 40 countries participated in the virtual meeting. The 2020 North America Conference on Lung Cancer was also a resounding success with 600+ delegates and experts from more than 35 countries participating. The fully virtual meeting was an opportunity for faculty to showcase novel research while facilitating rich discussions that will shape the future of treatment in lung cancer and other thoracic malignancies. We also made the difficult, yet necessary, decision to postpone the 2020 IASLC World Conference on Lung Cancer to January 2021 and convert it to a worldwide virtual event.

As we conclude 2020 and given the status of the pandemic, we are already making plans to conduct all of our 2021 meetings as worldwide virtual events. As circumstances improve, we will add live, in-person components to our virtual meetings.

The IASLC generated relevant content and engagement through myriad means in 2020. The *Journal of Thoracic Oncology*, with its Impact Factor of 13.357, is now among the top 5 percent of all oncology journals and is the leading thoracic oncology-focused journal. We also launched the *JTO Clinical and Research Reports* (JTO CRR) in 2020. As an open-access journal, the JTO CRR publishes a range of manuscripts from subset analyses of published trials to high-quality case reports.

As part of our collaborative partnership with the Lung Ambition Alliance, the IASLC continued its leadership of the IASLC Staging Project in preparation for the 9th edition, the Early Lung Imaging Confederation (ELIC), and the Major Pathological Response projects. In 2020, as a founding partner of the Alliance, the IASLC also led the way to expanding the Alliance with five additional project partners.

Other important scientific initiatives include our work within ASCO's Quality Oncology Practice Initiative where Brazilian and Spanish oncology practices can now access and improve their quality of care by participating in the QOPI lung cancer track. We are also engaged in CancerLinQ, a health information technology platform to enhance and improve the understanding and treatment of cancer. You can learn about this [work here](#). The IASLC Tobacco Control and Smoking Cessation Committee has continued to advance our message found in the [IASLC Smoking Cessation Declaration](#). The Nurses and Allied Health Professionals Committee continued the important work of developing educational materials and webinars, contributing articles to the ILCN and creating early-career opportunities to close the educational gaps in thoracic oncology. The IASLC, through the work of the Pathology Committee, also released the *IASLC Atlas of Diagnostic Immunohistochemistry* (IHC), to provide pathologists with up-to-date information on when to use IHC. You can order your copy of the IHC Atlas [here](#).

добро пожаловать

स्वागत Vítejte

Välkommen Bienvenue

The IASLC's commitment to people diagnosed with thoracic cancers was further enhanced in 2020 as we launched the second annual class of the Supportive Training for Advocates on Research & Science (STARS) program. Through STARS, prospective Patient Research Advocates (PRAs) are educated about how to read and interpret research articles and presentations, and are trained to communicate effectively with both the research and patient communities.

We were also excited to have launched a new Association Management System and the new IASLC website in 2020. These two significant infrastructure improvements will enhance the member experience, create streamlined communication with our members, and foster a more user-friendly experience for everyone. We have also successfully digitized the *Lung Cancer News* within our website. We encourage you to take a look at the new [IASLC.org](https://www.iaslc.org).

Finally, 2020 also presented multiple examples of persistent social inequity and injustice. The death of George Floyd and the ensuing demonstrations in the U.S. were reported widely around the globe. These incidents have called on our humanity and commitment to justice. As a truly international organization with members in 103 countries, the IASLC stated our shared resolve toward equity and a renewed commitment to foster a culture of respect. Read the [IASLC's Statement on Injustice](#).

We entered this pandemic period in a strong financial and operational position, poised to tackle its uncertainties and risks. The decisions we have made are intended to keep our community safe, to enhance the society's relevant offerings, and to position ourselves for a successful future. The key to meeting this moment has, of course, been you, our members. As we turn the calendar to 2021, please stay passionate about your work to advance lung cancer care and your involvement with the IASLC. Whether you are a scientist, clinician, nurse, or advocate, your contributions are fundamentally important in improving clinical outcomes and quality of life for patients and their loved ones. The IASLC is proud to be a partner, resource, and home for this global community of professionals. We look forward to our future collaborations, achievements and breakthroughs, as we work together to Conquer Thoracic Cancers Worldwide.

With our best wishes,

Dr. Tetsuya Mitsudomi,  
IASLC President

Dave Mesko,  
IASLC Chief Executive Officer

Добродошли

歡迎

Witamy  
ΑΙΟΠηα

Willkommen



Dr. Tetsuya Mitsudomi, IASLC President &  
Dave Mesko, IASLC Chief Executive Officer



Dr. Tetsuya Mitsudomi  
Osaka, Japan



INTERNATIONAL  
ASSOCIATION  
FOR THE STUDY  
OF LUNG CANCER

# MEMBERSHIP

## UNITED TOGETHER,

### Now, More Than Ever

#### IASLC's International and Multidisciplinary Membership

The foundation of the IASLC has always been its multidisciplinary and international membership base. As the outbreak of COVID-19 spread around the globe, IASLC members continued working in incredibly difficult circumstances to contain the outbreak and prevent further loss of life. By pooling our collective knowledge and expertise, the IASLC community worked together to create the [IASLC's Guide to COVID-19 and Lung Cancer](#), highlighting best practices, personal feedback, professional articles, tools, podcasts, webinars, and other educational opportunities for members to access during this difficult time.

Despite the worldwide focus on COVID-19, IASLC members from all corners of the world continued to push scientific advancements in multiple areas.

For more than 45 years, IASLC members have collaborated globally to advance our mission of conquering thoracic cancers worldwide. By participating in educational events such as the IASLC's 2020 Hot Topic Meeting: Liquid Biopsy, the 2020 North America Conference on Lung Cancer, and the 2020 World Conference on Lung Cancer | Singapore, lung cancer specialists gained access to the latest research and scientific findings in thoracic oncology—further advancing their profession through education and development opportunities.


This year, the IASLC invested in new technologies and infrastructure to enhance the IASLC member experience and has launched an entirely new IASLC database, member portal, and website. The new [IASLC member portal](#) is fully customized, easy-to-navigate, and is a fully comprehensive hub where members can access key member benefits including the [Journal of Thoracic Oncology](#), the virtual library, and the IASLC member directory. New functionality in the portal allows members to renew their membership with additional payment methods including PayPal, American Express, and JCB, and securely displays their profile information for easy updates and features like membership auto-renewal and quick check-out in the store.

Comprising every specialty in lung cancer, our committee members and their contributions are at the heart of the society. As part of our 13 committees, ranging from patient advocacy to our scientific committees and more, IASLC committee members continue to contribute their specialized skills and talents to help shape the work of the organization, develop educational content, plan annual meetings, contribute to publications authored by the IASLC, and more. This year, the IASLC Pathology Committee released the new [Atlas of Diagnostic Immunohistochemistry](#). This Atlas plays a key role in the diagnosis of thoracic tumors and provides pathologists up-to-date information to help them determine when to use IHC, and how to correctly interpret the results. Additionally, the IASLC Tobacco Control and Smoking Cessation Committee developed "Tobacco Control Moments" which were shared at the 2020 North America Conference on Lung Cancer. These were short and focused video updates on key topics to provide relevant information to healthcare providers.

Regardless of your career phase, specialty, or geographic location, the IASLC is your hub for education and collaboration. The IASLC continues to put our members first—so they can go above and beyond for patients—by offering discounted registration fees to meetings and educational events, complimentary access to the JTO, and discounted publication fees for the newest open-access IASLC journal, [JTO Clinical and Research Reports](#) (JTO CRR). Another great member benefit is the IASLC Online Member Directory which allows members to directly connect and collaborate. In addition, the IASLC is proud to offer members access to free continuing medical education opportunities, volunteer opportunities, and more.






## MEMBERS BY COUNTRY/REGION



**6,228**  
MEMBERS TOTAL

**FEMALE**  
**37%**  
**MALE**  
**61%**  
**UNKNOWN**  
**2%**


## MEMBERS BY AGE



### Top 10 Countries for Membership




## MEMBERS BY PRIMARY SPECIALTY



\* Other includes: Hematology, Pharmacy, Smoking Cessation, Resp. Therapy/Physiotherapy, Patient/Survivors, Caregivers and Unknown.

## LOCATION-PROFESSIONAL ACTIVITY/PRACTICE





# WEBSITE INTEGRATION AND MEMBER PORTAL

Never before has technology mattered more to our daily lives and professional communications. Recognizing the many demands placed on our members' time, the IASLC has made upgrades to its member database and website. Members can now easily access their account data and their membership benefits via quick links on the home page of [IASLC.org](https://iaslc.org). Members and nonmembers can view and search for more timely and relevant news on every page of the site. Articles from the *Journal of Thoracic Oncology* and *JTO Clinical Research Reports* are available on the new [IASLC.org](https://iaslc.org), organized by theme and relevance. And, meetings and webinars are now searchable in numerous ways, including by presence of CME-accreditation.

In the new customized and easy-to-navigate **member portal**, IASLC members can now renew their memberships and make donations to the ILCF with additional payment options including PayPal, American Express, and JCB, among others. Memberships can also be set to securely auto-renew immediately upon expiration, ensuring ease for users and continuous access to member benefits year after year.


Members can now access a clear and comprehensive view of their user profile and can easily update contact information including social media accounts. They also can directly and easily connect with colleagues around the globe utilizing the improved IASLC member directory with direct messaging capabilities.

While patient advocates have long been recognized as contributing members of the association, the IASLC was pleased to announce the formation of a specific membership category in 2020: Patient Advocate Membership. This membership is intended for individuals who work for a patient advocacy organization or are professionally involved with patient advocacy efforts.



The IASLC also introduced new technology tools to enhance committee engagement. IASLC committee members can now utilize new private Community Groups, found within the IASLC member portal, to share files, post secure updates, and easily keep up-to-date with committee activity.





Publications, resources, and guidelines can be quickly and easily accessed from the updated [IASLC Website](#) and [IASLC Store](#). Members and nonmembers alike can explore an expansive catalog of Atlases, staging resources, new and archived guidelines, and materials for patients and providers.

Whether you are an early-career physician looking for grant and mentoring opportunities, or a patient advocate looking to take the next step toward communicating more effectively about lung cancer research, there are unique and robust offerings for you.



We at the IASLC are excited for our stakeholders to explore the new offerings and to provide feedback. For timely and relevant news and association information, visit [IASLC.org](https://www.iaslc.org). To go directly to the member portal, visit [my.iaslc.org](https://my.iaslc.org). Contact us with any questions or comments at [membership@iaslc.org](mailto:membership@iaslc.org).

# EDUCATION & CONFERENCES

This year it was imperative for the IASLC to adapt its live meetings to virtual conferences, given the serious public health concerns and restrictions on travel and in-person gatherings. As a result, the IASLC pivoted to a fully online platform with pre-recorded sessions, live, and on-demand content.

The IASLC received positive feedback from attendees during our initial online offerings, with specific recognition of the innovative content and live panel discussions, and Q&A opportunities. As the year progressed, the IASLC Program Committees continued to place a high priority on interactivity in the virtual environment, such as live Q&A; live tumor board panels with break out rooms for discussions; networking lounges; enhanced chat functions with delegates, faculty, patients, and exhibitors; conversation boards; and live poster discussions. While we missed seeing faculty, delegates, and friends in person, going virtual allowed the IASLC to provide a global platform for even greater attendance and accessibility.

## IASLC 2020 CONFERENCES AND EVENTS

### › 2020 SIXTH AACR-IASLC INTERNATIONAL JOINT CONFERENCE | In-person Event: San Diego, California, USA | January 2020

In conjunction with the American Association for Cancer Research (AACR), the IASLC held the sixth biennial international conference on lung cancer science. Nearly 250 attendees from diverse fields (physicians, patient advocates, and scientists in basic, translational, and clinical lung cancer research) discussed recent advances and established new collaborations. Session topics included preneoplasia and early detection, immunotherapy, molecular targets, drug resistance, tumor progression, and metastasis.

### › IASLC 2020 LUNG CANCER TARGETED THERAPIES MEETING | In-person Event: Santa Monica, California, USA | February 2020

The IASLC 2020 Targeted Therapies of Lung Cancer Meeting (TTLC20) was held at the Fairmont Miramar Hotel in Santa Monica, California from February 19-22, 2020. Meeting Chairs Drs. Paul A. Bunn, Jr., Roy Herbst, Leora Horn, and Suresh Ramalingam welcomed more than 700 participants from 15 countries to share information about ongoing clinical trials of the newest therapies for lung cancer. Participants were encouraged to actively participate in discussions and engage with industry supporters. Presenters summarized the data on relevant targets for new therapies and shared data on preclinical and early clinical data for each of the drugs directed against these targets. At the TTLC20, 36 abstract submissions were received, 33 education awards were presented, and 13 exhibitors participated in the meeting, with Genentech as the Diamond sponsor.



IASLC 2020 Lung Cancer Targeted Therapies Meeting



› **FDA/CDER-AACR-IASLC WORKSHOP TO ADDRESS THE CRITICALITY OF TOBACCO USE ASSESSMENT IN ONCOLOGY THERAPEUTIC TRIALS | In-person Event: Silver Springs, Maryland, USA | February 2020**

This meeting provided a forum for open discussion between the public, academia, industry, FDA, and other stakeholders to improve the public understanding of the significance of persistent tobacco use on outcomes, clinical trials that test therapies for cancer, cardiovascular, and pulmonary diseases. During this meeting, the FDA, AACR, and the IASLC expressed a willingness to leverage their combined strengths to develop substantive activities to address the criticality of assessing the use of tobacco in oncology clinical trials.

› **IASLC 2020 WCLC VIRTUAL PRESIDENTIAL SYMPOSIUM | Worldwide Virtual Event | August 2020**

The IASLC presented practice-changing studies and recent advances in thoracic oncology at the IASLC WCLC 2020 Virtual Presidential Symposium (VPS) on August 8, 2020. With 2,770 registrants, the VPS served as a prelude to the innovative research that was presented at the WCLC 2020 worldwide virtual event in January 2021.

› **IASLC 2020 HOT TOPIC MEETING: LIQUID BIOPSY | Worldwide Virtual Event | October 2020**

The state-of-the-art IASLC 2020 Hot Topic Meeting: Liquid Biopsy gathered international and multidisciplinary experts in the field of liquid biopsy in lung cancer to present and discuss recent advances in liquid biopsy technology and clinical applications. The meeting Chairs, Drs. Maria Arcila, David Gandara, and Christian Rolfo organized a two-day program with an internationally renowned faculty. Topics included the basics of liquid biopsy to real world challenges for a worldwide application, a molecular tumor board, as well as relevant clinical trials, and updates on the FDA perspective on the use of Liquid Biopsy in NSCLC, and data leveraging ctDNA to detect minimal residual disease following surgery. With more than 500 registrants from nearly 50 countries, 42 abstracts submitted, and 8 industry sponsors, this worldwide conference was a milestone accomplishment for the IASLC.

› **IASLC 2020 NORTH AMERICA CONFERENCE ON LUNG CANCER | Worldwide Virtual Event | October 2020**

The 2020 North America Conference on Lung Cancer, chaired by Drs. Julie Brahmer, Jessica Donington, Heather Wakelee, and Everett Vokes, provided wide-ranging and multidisciplinary content including keynote lectures, mini oral, and poster presentations, affording delegates the opportunity to learn, share knowledge, and network with delegates from around the world. With more than 600 attendees from 43 countries, delegates enjoyed research from 108 submitted abstracts, and booths from 17 industry sponsors.

The NACLC featured presentations from distinguished faculty on novel early-stage disease solutions and reviews of clinical trials and presentations on first-line targeted therapy for patients with rare driver mutations. Stigma presentations, along with the role of surgery in oligometastatic lung cancer, were also featured. The IASLC also incorporated patient perspective videos and showcased brief educational presentations by members of the Tobacco Control and Smoking Cessation Committee highlighting the importance of delivering smoking cessation services in a telehealth environment, lung cancer screening, and smoking cessation clinical trials.



**Dr. Charu Aggarwal**  
Philadelphia, PA

 **2020 Presidential Symposium**

**AUGUST 8, 2020 | WORLDWIDE VIRTUAL EVENT**

  **2020 HOT TOPIC MEETING: LIQUID BIOPSY**

**OCTOBER 2-3, 2020 | WORLDWIDE VIRTUAL EVENT**

  **2020 North America Conference on Lung Cancer**

**OCTOBER 16-17, 2020 | WORLDWIDE VIRTUAL EVENT**



# 2020 World Conference on Lung Cancer Singapore

JANUARY 28-31, 2021 | WORLDWIDE VIRTUAL EVENT

The IASLC made the early and intentional decision to move the 2020 World Conference on Lung Cancer (WCLC 2020) to January 2021 in hopes that a live meeting would still be possible. When it became clear that the meeting would not be possible in early 2021, the IASLC leadership and Board of Directors made the difficult, but unavoidable, decision to pivot to a fully virtual meeting.

After a long-standing tradition of holding a live in-person WCLC meeting in different locations all over the world, the IASLC was looking forward to holding the WCLC in Singapore and had already begun planning with the Conference Chairs. Despite the delivery format change, the WCLC Conference Chairs, Drs. Yi-Long Wu, Daniel Tan, and Ross Soo continued the IASLC's tradition of delivering a top-notch educational program marked by practice-changing abstracts.

## WCLC 2020 AWARD WINNERS: Recognizing Excellence in the Lung Cancer Field

### 2020 Distinguished Service Awards:

In addition to serving as a source for exceptional education, the 2020 WCLC also represents an opportunity to recognize excellence in the field of lung cancer research. Each year, the association distributes awards that recognize lifetime achievement in specific areas of practice, with the most significant honors—the IASLC Distinguished Service Awards—being distributed during the WCLC Opening Ceremony.

**2020**  
**Adi F. Gazdar**  
**IASLC Merit**  
**Award**



**Alex A. Adjei, MD, PhD**  
Professor of Oncology and  
Pharmacology Consultant,  
Medical Oncology Mayo Clinic,  
Rochester, MN, USA

**2020**  
**Paul A. Bunn, Jr.**  
**Scientific**  
**Award**



**Joan H. Schiller, MD**  
Medical Oncology Specialist,  
Inova Fairfax Medical Campus,  
Fairfax, VA, USA

**2020**  
**Joseph W. Cullen**  
**Prevention/Early**  
**Detection Award**



**Pan-Chyr Yang, MD, PhD**  
National Taiwan University  
College of Medicine Professor,  
Department of Internal Medicine,  
Taipei City, Taiwan

**2020**  
**Mary J. Matthews**  
**Pathology/Translational**  
**Research Award**



**Caroline Dive, CBE, PhD,**  
**FBPhS, FMedSci**  
Professor of Cancer  
Pharmacology, University of  
Manchester, United Kingdom

## 2020 LECTURESHIP AWARDS

### 2020 ROBERT J. GINSBERG LECTURESHIP AWARD FOR SURGERY

Eric Lim, MD, MSc, FRCS, Professor of Thoracic Surgery, The Royal Brompton Hospital, London, United Kingdom

### 2020 CLIFTON F. MOUNTAIN LECTURESHIP AWARD FOR STAGING

Enrico Ruffini, MD, Department of Thoracic Surgery University of Torino, Torino, Italy

### 2020 IASLC LECTURESHIP AWARD FOR TOBACCO CONTROL AND SMOKING CESSATION

Wanda de Kanter, MD, Consultant, The Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands

### 2020 JAMES D. COX LECTURESHIP AWARD FOR RADIATION

Walter J. Curran, Jr., MD, FACR, FASCO, Lawrence W. Davis Chair of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia, USA

### 2020 FRED R. HIRSCH LECTURESHIP AWARD FOR TRANSLATIONAL RESEARCH

Sanja Dacic, MD, PhD, Professor of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

### 2020 TSUGUO NARUKE LECTURESHIP AWARD FOR SURGERY

Samina Park, MD, Seoul National University Hospital, Seoul, Republic of Korea

### 2020 DANIEL C. IHDE LECTURESHIP AWARD FOR MEDICAL ONCOLOGY

Myung-Ju Ahn, MD, Samsung Medical Center, Seoul, Republic of Korea

### 2020 IASLC LECTURESHIP AWARD FOR NURSES AND ALLIED HEALTH PROFESSIONALS

Mary Duffy, RSCN, Peter MacCallum Cancer Centre, Lung Nurse Coordinator, Melbourne, Victoria, Australia

### 2020 HEINE H. HANSON LECTURESHIP AWARD FOR SMALL CELL LUNG CANCER

Lauren Byers, MD, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center Houston, Texas, USA

Learn more about the IASLC's [Distinguished Service Award Winners](#), [Lectureship Award Winners](#), and [Advocacy Winners](#).



**Dr. Hidetoshi Hayashi**  
Osaka, Japan

## WCLC MEDIA COVERAGE

**32**

NEWS RELEASES  
ISSUED

**13**

SCI. ABSTRACT  
NEWS RELEASES

**117**

REMOTE JOURNALISTS

**3,734**

STORIES IN SPANISH  
MEDIA OUTLETS

**3,683**

STORIES IN ASIAN  
MEDIA OUTLETS

**65,600**

TOTAL MEDIA MENTIONS

VIEWS OF IASLC NEWS  
RELEASES ON EUREKALERT

**50,624**

BY JOURNALISTS

**3**

PRESS BRIEFINGS

NEW FOLLOWERS ADDED ACROSS  
ALL SOCIAL PLATFORMS

**500+**

TOTAL NUMBER OF COUNTRIES  
IN WHICH MEETING WAS COVERED

**123**

UNIQUE ONLINE VISITORS  
FEATURING WCLC COVERAGE

**67,600,000,000**

## NUMBER OF INVITED SPEAKERS

**240**

NUMBER OF PLENARY SPEAKERS

**43**

INVITED SESSION CHAIRS

**46**

INVITED SPEAKERS

**150**

DISCUSSANTS

**45**

NUMBER OF POSTER PRESENTATIONS

**963** **1,500+** **93**

ACCEPTED  
POSTERS

E-POSTERS

FEATURED  
POSTERS

NUMBER OF ORAL ABSTRACT SESSIONS

**11**

SESSIONS

**45**

ABSTRACTS

NUMBER OF MINI ORAL  
ABSTRACT SESSIONS

**13**

SESSIONS

**108**

ABSTRACTS

EDUCATION AWARDS

**14x**

EARLY CAREER

**10x**

DEVELOPING  
NATIONS

# SCIENTIFIC AFFAIRS

## The **LungAmbition** Alliance

### **Lung Ambition Alliance:** STRONGER TOGETHER

The IASLC has formed an alliance with the Global Lung Cancer Coalition (GLCC), Guardant Health, and AstraZeneca to accelerate the pace of lung cancer survival worldwide. This collaborative effort allows scientists, specialists, advocates, and patients to break the barriers limiting progress with a goal to double 5-year survival rates of lung cancer by 2025. Together, we have identified three key areas of focus that will allow us to drive innovation and improvements in the field and, ultimately, to improve the lives of lung cancer patients worldwide.

## Three Research Pillars



### **Pillar 1**

Increasing lung cancer screening and early diagnosis rates



### **Pillar 2**

Accelerating the delivery of innovative therapies



### **Pillar 3**

Improving the quality of care to provide the best possible outcomes for patients

The Lung Ambition Alliance was pleased to welcome five new Project Partners to the Alliance in 2020:



## Lung Ambition Alliance Flagship Scientific Projects

The Lung Ambition Alliance (LAA) currently oversees multiple groundbreaking scientific projects that bring together oncologists, radiologists, surgeons, pulmonologists, researchers, patients, advocates, and pharmaceutical companies from around the world. These projects span a wide range of topics, from updating the current TNM Staging System, to investigating tumor response, to neoadjuvant therapies that help drive innovation and collaboration in the field of lung cancer. [Learn more about all of the LAA Projects.](#)

### › MPR: Major Pathologic Response

Before undertaking the MPR project by the IASLC and the LAA, there were no established guidelines for processing and evaluating resected lung cancer specimens and there was a lack of precise definitions for the degree of pathological response following neoadjuvant therapy. These recommendations were published in the *Journal of Thoracic Oncology*. The IASLC has begun working on step two of the MPR project, which aims to determine a global cadre of pathologists' reproducibility of histological MPR and CPR assessments in surgical resection specimens of lung cancer patients treated with neoadjuvant immune checkpoint inhibitors with and without chemotherapy by implementing the published IASLC recommendations. Each of these steps will help the IASLC and LAA establish Pathologic Response (PR), Major Pathologic Response (MPR), and/or Complete Pathologic Response (CPR), in surgical resection specimens following neoadjuvant therapies as predictors and surrogate markers of long-term clinical benefit in patients with resected stage I to III lung cancer. [Learn more about the MPR project.](#)

### › Early Lung Imaging Confederation (ELIC):

Effective screening is critical to detecting and diagnosing lung cancer early and thus increasing patient survival. The Early Lung Imaging Confederation (ELIC) is an international alliance of collaborating individuals and institutions who share a vision to develop a globally distributed, privacy-secured, lung cancer imaging database, and computational analysis environment. The main goal of ELIC is to support the development of deep learning methods or artificial intelligence approaches to detect early lung cancer and other diseases using thoracic CT images. This work will allow medical professionals to characterize small pulmonary nodules and surrounding structures, and to measure responsiveness to therapeutic interventions. The IASLC is currently facilitating the uploading of cases into the database and had approximately 600 cases uploaded by December 2020. [Learn more about the ELIC project.](#)



ELIC

### › TERA-VOLT: Supporting a global effort to understand the impact of COVID-19 on thoracic malignancies

The COVID-19 pandemic has presented unique challenges for treating thoracic malignancies. To increase the understanding of COVID-19 as it relates to lung cancer and other thoracic malignancies, the IASLC, on behalf of the LAA, is pleased to support TERA-VOLT, a global consortium that was created to understand the impact of COVID-19 on patients. [Learn more about the TERA-VOLT Project.](#)



TERA-VOLT



## Staging: Improving Lung Cancer Staging through International Collaboration

For more than 20 years, the IASLC Lung Cancer Staging Project has provided valuable recommendations for the TNM classification of lung cancer—jointly published by the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC). The IASLC is currently gathering data to inform the 9th edition of the TNM Staging System, which for the first time, will include new data elements such as gene mutations, fusions, number alterations, and protein expression levels. The goal of these additional tumor characteristics is to significantly enhance the accuracy of the Staging System, leading to more precise treatment regimens and increased patient survival. As of November 2020, the following number of cases have been collected from more than 20 countries:

**54,789**  
LUNG CANCER  
CASES

**436**  
MESOTHELIOMA  
CASES

**7,183**  
THYMIC  
MALIGNANCIES  
CASES

We need your help! **Submit data to the 9th edition** of the Staging Project today! Your contribution will help us to build the most robust global dataset for lung cancer, mesothelioma, and thymic malignancies.

For more information on the IASLC's Staging Project or how to contribute data, please visit [www.IASLC.org/staging](http://www.IASLC.org/staging).




**Dr. Giorgio Scagliotti**  
Torino, Italy



# LUNG CANCER CONSIDERED



with **Dr. Stephen Liu** and **Dr. Narjust Duma**  
an IASLC Podcast



**Lung Cancer Considered** has released more than 50 podcasts which have been viewed and streamed more than 17,000 times globally, since its inception in 2019. **Lung Cancer Considered** features the researchers, healthcare professionals, patients, and advocates who are making a difference in the advancement of the study and treatment of thoracic malignancies. We're happy to announce new hosts, Dr. Narjust Duma and Dr. Stephen Liu, who will bring a new perspective to the podcast series.

**Listen here and join in  
the conversation.**

## Other IASLC Scientific Projects

### › Molecular Testing Survey

In January 2020, the results of the IASLC Global Survey on Molecular Testing in Lung Cancer were published in the *Journal of Thoracic Oncology*. The purpose of this survey was to assess the current prevalence and practice of molecular testing and to identify barriers or gaps that exist and thus improve molecular testing globally. A total of 2,537 respondents from 102 countries participated in the survey, including those who test and treat patients, those who perform and interpret assays, and those who acquire tissue for testing. The results showed that awareness and adoption of molecular testing for lung cancer are still relatively low around the world. Although results varied by region, the five most frequent barriers cited in all regions were cost, quality and standards, access, awareness, and turnaround time. The findings of this survey can inform the development of solutions that can be applied broadly and those that can be tailored to specific regions. The IASLC is currently developing educational initiatives aimed to improve technical knowledge and awareness of guidelines. Guidelines are being updated with state-of-the-art evidence-based practices. [Learn more and read the entire survey.](#)

### › Tobacco Control and Smoking Cessation

This year the IASLC Tobacco Control and Smoking Cessation Committee developed “Tobacco Control Moments” that were shared at the 2020 North America Conference on Lung Cancer. These short educational talks discussed how to incorporate delivering smoking cessation across the cancer care continuum, the importance of smoking cessation services in the era of telehealth, the integration of smoking cessation into lung cancer screening through clinical trials, and tobacco product updates and myth busters.

In February 2020, the IASLC also held a workshop in conjunction with the FDA and AACR based on the 2019 IASLC Declaration on Tobacco Cessation after Cancer Diagnosis. This workshop brought together thought leaders and the public to discuss the importance of incorporating smoking status as a required data element for all prospective clinical trials as well as the need for trial design to effectively incorporate tobacco cessation interventions.

### › Quality Oncology Practice Initiative (QOPI)

In 2020, the IASLC expanded its partnership with the American Society of Clinical Oncology (ASCO) and the QOPI program in Spain. We are now closely working with the Foundation for Excellence and Quality in Oncology (ECO) to improve the quality of lung cancer care across Spain. The IASLC also continued our efforts in Brazil and expect to build upon these partnerships in the coming years. [Learn more about the QOPI project.](#)

The logo for the Quality Oncology Practice Initiative (QOPI) in partnership with ASCO. It features the word "ASCO" in blue and "QOPI" in green.

### › Diagnostic Immunohistochemistry Atlas

This year, the IASLC Pathology Committee, led by the editorial group of Drs. Yasushi Yatabe, Alain Borczuk, Wendy Cooper, Sanja Dacic, Keith Kerr, Andre Moreira, and Ming Tsao, developed the *Atlas on Diagnostic Immunohistochemistry* (IHC). This Atlas is an expansion on the JTO publication from 2019 and serves as a guidebook for pathologists as they continue to improve the diagnosis of thoracic cancers through IHC. [Order your IHC Atlas.](#)

### › CancerLinQ

The IASLC is working collaboratively with ASCO to expand the specialized expertise informing CancerLinQ®, a health information technology platform, developed by oncologists for oncologists, to enhance and improve the understanding and treatment of cancer. The IASLC is contributing thought leadership and subject matter expertise to CancerLinQ, including aspects of clinical practice related to the diagnosis and management of lung cancer, the identification and development of clinical quality measures for thoracic oncology, and other relevant content. [Learn more about CancerLinQ](#) and stay tuned for the IASLC’s research from data in 2021.

### › Impacts of COVID-19 on International Lung Cancer Clinical Trials Project

The COVID-19 pandemic has impacted cancer clinical trials. Although we have studies focused on the impact of the pandemic on new cancer diagnoses and cancer clinical trial participation in general, none have focused specifically on the impact of COVID-19 on lung cancer clinical trials. It is important for the lung cancer community to understand the impacts of COVID on lung cancer studies and identify measures to mitigate those impacts in order to continue to move the science of lung cancer treatment forward, and to improve patient outcomes.

The purpose of this study was to determine the extent to which lung cancer clinical trials have been impacted by the pandemic across the whole spectrum of care in all regions of the world and how those impacts have been mitigated. Additionally, the study will identify other mitigation measures, and potentially modify the structure of the clinical trials process to increase patient and physician participation to expedite the expansion of effective treatment options for lung cancer patients. This survey will engage clinicians, industry partners, and regulatory bodies and will be released in early 2021.



**Dr. Navneet Singh**  
Chandigarh, India

# JTO & JTO CRR

## Serving the Lung Cancer Community Through Cutting-Edge Publications

### JOURNAL OF THORACIC ONCOLOGY

The *Journal of Thoracic Oncology* (JTO), the IASLC's official journal, has become the field's authoritative publication for education and information related to all aspects of thoracic malignancies. The JTO includes original research, reviews, and opinion pieces, and reaches a diverse audience, including epidemiologists, statisticians, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, and research scientists with a special interest in thoracic oncology. During the COVID-19 pandemic, the JTO rapidly reviewed and published articles that informed expert decision-making, including the first article on pulmonary pathology of lung cancer patients with COVID-19.

The JTO's influence on the field is represented by its increased impact factor, which has climbed dramatically in recent years. From having an impact factor of 6.595 in 2016, the JTO's impact factor rose to 12.460 in 2018 and then again to 13.357 in 2019. Additionally, it ranks 11th out of all oncology journals and 3rd out of all respiratory system publications.

**JTO**  
Impact Factor  
increases to  
**13.357!**

### J T O R A N K I N G S :

#### ONCOLOGY JOURNALS

**11**  
OUT OF  
**244**  
IN 2019



#### RESPIRATORY JOURNALS

**3**  
OUT OF  
**64**  
IN 2019

“JTO CRR’s success and continued growth in its first year is a reflection of the support of our readers, authors, and reviewers. The journal will publish monthly starting in 2021 to accommodate the many meritorious articles it is receiving. This open access journal broadens the reach of the IASLC throughout the world, offering unfettered access to the thoracic oncology community.”



-Alex A. Adjei, MD, PhD  
Editor-in-Chief

### JTO CLINICAL AND RESEARCH REPORTS

JTO Clinical and Research Reports (JTO CRR) successfully launched in 2020. This journal complements the JTO by offering authors a gold open-access publication option. JTO CRR published four issues that included more than 50 articles in 2020. Based on the abundance of quality research articles, JTO CRR will begin publishing monthly starting in January 2021. Learn more about the [JTO CRR](#).

JTO 2020  
ARTICLE DOWNLOADS  
**2,883,298**

JTO CRR 2020  
ARTICLE DOWNLOADS  
**104,994**



Dr. Clarissa Mathias  
Bahia, Brazil



# PATIENT ADVOCACY

Advances in the care of patients with lung cancer and novel treatment options have grown exponentially over the past decade. The IASLC recognizes the importance and value that patients with lung cancer, their caregivers, and patient advocates bring to the organization. We hope to increase the pace of knowledge sharing and advancements in care by offering the patient advocate audience opportunities to:

- › Attend conferences;
- › Form relationships with researchers and care providers;
- › Lend their voices, sitting side-by-side with researchers and members of the care team; and
- › Share their perspectives and experiences.

The IASLC strives for inclusivity and offers multiple opportunities to support individuals on their journeys as patient research advocates.

## IASLC Supportive Training for Advocates on Research & Science (STARS)



The IASLC STARS program aims to increase the number of patient research advocates (PRAs) equipped to provide accurate scientific translation in their groups for patients with lung cancer and their caregivers and to provide the patient perspective for lung cancer research and policy.

In its second year, and amid the COVID-19 pandemic, the 6-month program went fully virtual. To ensure maximum knowledge sharing and opportunities to network, STARS partnered with Research Advocacy Network (RAN). The RAN platform allowed PRAs and Mentors to access various learning modules and then come together weekly to discuss and collaborate. STARS was developed by the IASLC in collaboration with lung cancer research advocates and patient advocacy nonprofits.

## 2020 STARS Contributing Organizations



The IASLC is proud to support the following individuals in the 2020 IASLC **STARS** Program

## STARS MENTORS



Andrew Ciupek  
USA



Ivy Elkins  
USA



Lillian Leigh  
AUSTRALIA



Melissa Crouse  
USA



Merel Hennink  
NETHERLANDS




Sue McCullough  
AUSTRALIA

## PATIENT RESEARCH ADVOCATES



Anita McGrath  
AUSTRALIA



Anne Marie Cerato  
CANADA



Caleb Egwenu  
NIGERIA



Christine Qiong Wu  
CANADA



Debra Violette  
USA



Diane Colton  
CANADA




Erika Hlavacek  
USA

## PATIENT RESEARCH ADVOCATES CONTINUED



Kimberly Lester  
USA



Laura Book  
USA




Lily Huang  
NEW ZEALAND




Lisa Briggs  
AUSTRALIA



Terri Conneran  
USA



Tom Wood  
AUSTRALIA



Tomma Hargraves  
USA

### 2020 STARS Sponsors



**Terri Conneran**  
Charlotte, North Carolina

# CANCER CARE TEAM AWARDS

The IASLC Cancer Care Team Award is a prestigious award which aims to honor and recognize outstanding patient care served by multidisciplinary teams working together. Nominations are accepted from all over the world by individual patients with lung cancer and/or their caregivers/care partners. The IASLC is proud to honor the following winning teams of the 2020 IASLC Cancer Care Team Award:

#### OVERALL Winner: North America

**Mount Sinai Hospital**  
New York, New York

Andrea Wolf, MD  
Marissa Senise, NP  
Jorge Gomez, MD  
Jessica Fernandez, PA  
Thomas Marron, MD, PhD  
Stephanie Lehrman, LCSW  
Kenneth Rosenzweig, MD

#### Latin America

**Instituto De Oncologia 'Angel H. Roffo'**  
Buenos Aires, Argentina

Monica Castro, MD  
Mara Bonet, MD  
Carolina Gabay, MD  
Pablo C. Morgado, MD

#### Europe

**Klinikum Würzburg Mitte**  
Würzburg, Germany

Jens Kern, MD  
Jürgen Wolf, PhD  
Gabi Hautsch, RN  
Danjouma Cheufou, MD

#### Asia/ROW

**Beilinson Hospital - Rabin Medical Center**  
Petach Tikva, Israel

Alona Zer, MD  
Tal Danin Ovad, BA  
Hiba Rechtes, RN



2020 IASLC Cancer Care  
Team Award Video





# 2020 LUNG CANCER AWARENESS MONTH

The IASLC is a proud partner and founder of the LCAM Coalition. The Coalition is composed of more than 40 nonprofit organizations with a focus on lung cancer. Each year in November, the Coalition unites to generate public awareness about the impact of lung cancer, promote events of the Coalition partners, and share available resources on potentially life-saving treatment options.

## 2020 LCAM SPONSORS

### 2020 CHAMPION SPONSORS



### 2020 SURVIVORSHIP SPONSORS



### 2020 RESEARCH SPONSORS



**Debbie Pickworth,**  
Westland, Michigan

# WEBINARS

In response to the COVID-19 pandemic, the IASLC conducted a series of CME-accredited webinars providing a global forum for multidisciplinary perspectives on the diagnosis and management of lung cancer within the COVID-19 environment.


## 2020 IASLC Webinars: COVID-19

- › Practical Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement. (April 20, 2020)
- › Impact of COVID-19 on Treatment of Lung Cancer Patients with Local and Locoregional Disease. (April 28, 2020)
- › Systemic Therapy for Advanced Stage Lung Cancer During the COVID-19 Pandemic (April 29, 2020)
- › Impact of COVID-19 on Treatment of Lung Cancer Patients with Local and Locoregional Disease. (May 11, 2020)
- › Supportive Care for Lung Cancer Patients During COVID-19 (December 8, 2020)


## Other topics

- › Highlights of ASCO (July 31, 2020)
- › Cancer Drug Development in the Era of Precision Medicine (November 2, 2020)

## ATTENDEES BY CONTINENT



North America



Asia



Europe




Rest of World



**Dr. Sonam Puri and  
Dr. Jaskaran Sethi**  
Salt Lake City, Utah


## ATTENDEES BY PRIMARY SPECIALTY



**1,736**  
TOTAL ATTENDANCE

**619**  
IASLC MEMBERS

## ATTENDEES BY COUNTRY



Click  
to Access  
Recorded  
Webinars

# CORPORATE RELATIONS

With the advent of the all-virtual era, the IASLC worked to provide opportunities to bring corporate partners and our global audience together. There are so many ways to partner with the IASLC—by sponsoring an upcoming meeting, project, or activity. We would like to extend a thank you to our top corporate partners of 2020.

To learn more about becoming a Corporate Supporter of the IASLC, please contact us at [corporaterelations@iaslc.org](mailto:corporaterelations@iaslc.org).

**AMGEN**<sup>®</sup>  
Oncology

**AstraZeneca**

 **Daiichi-Sankyo**

**Genentech**  
*A Member of the Roche Group*

 **Jazz Pharmaceuticals**

 **MERCK**



 Bristol Myers Squibb™

*Lilly* | ONCOLOGY

Janssen  Oncology

 NOVARTIS

 Takeda

# INTERNATIONAL LUNG CANCER FOUNDATION



The International Lung Cancer Foundation aims to accelerate the pace of thoracic malignancy research, to inspire researchers to focus their careers on lung cancer, and to reduce the worldwide lung cancer mortality rate.

Donations from patients, caregivers, and those individuals passionate about accelerating the pace of lung cancer research, as well as from our organizational and corporate partners, directly fund our Research Awards. These Research Awards provide early-career researchers with vital funding opportunities, fostering tomorrow's lung cancer visionaries and achieving milestones in patient care.

## Honoring a Special 2020 Contribution

In early 2020, the ILCF received a generous gift of \$200,000 from Dr. Fred Hirsch. "I've dedicated my career to eradicating lung cancer," Hirsch stated. "Over the last decade, and particularly within the last few years, we've seen great momentum with treatment, and I believe that for this momentum to continue, we need to support research now more than ever. I am proud to support the ILC Foundation, especially knowing that my contribution will directly fund research and help to develop the next generation of lung cancer specialists."

Dr. Hirsch's gift will help the ILCF inspire hope through research by funding four one-year Research Awards.

## 2020 Fundraising

At the ILCF, our 2020 fundraising got off to a great start. Three IASLC members and stage I lung cancer survivors—Christie Malnati, Sandy Shea, and Kathy Weber—came together as "Team Hope" to participate in the 2020 Lung Cancer Survivors Super Bowl Challenge, part of the Chris Draft Family Foundation. Through the Super Bowl Challenge, Team Hope raised \$11,731.50! The ILCF was excited and grateful to be selected as the beneficiary of their fundraising.

One goal of our 2020 fundraising strategy was to increase the number of individual donations by making donating easier. By including an option to donate in the meetings registration process and in the membership renewal process, as well as by making our online donation process easier, we generated just over \$54,000 from 657 donors—far surpassing our previous high number of individual donors of 248 in 2018.



**Dr. Fred Hirsch presenting the ILCF with a generous donation to fund further lung cancer research. Pictured from left: Dr. Tetsuya Mitsudomi, Dr. Fred Hirsch, Dave Mesko, and AnnMarie Priest.**

## 2020 Research Awards

In 2020, the Foundation awarded 11 Research Awards totaling just over \$1.1 million. This year's award recipients are working across the globe—in Belgium, Canada, Ireland, Italy, Spain, and the United States—to eradicate lung cancer and other thoracic malignancies. Our Research Awards program is made possible by individual donations from people like you and by Foundation partners and organizations.

### 2020 Foundation Partners



### 2020 Funding Partners



Drs. Andrea Bezjak, Heather Wakelee, and Joan Schiller serve as leaders to both the scientific and IASLC community.



At the 2019 World Conference on Lung Cancer in Barcelona, the ILCF celebrated the global recipients of ILCF Research Awards. Pictured from left: Dr. Warren Naselsky, University of Maryland School of Medicine (USA); Dr. Hanbo Chen, University Medical System Amsterdam (Europe); Dr. Roberto Ferrara, I.R.C.C.S. National Cancer Institute (Europe); Dr. Ashwin Somasundaram, UPMC Hillman Cancer Center (USA); and Dr. Tejas Patil, University of Colorado (USA).

# ILCF BOARD OF DIRECTORS



**David Carbone**  
Chair  
United States



**David Gandara**  
Vice Chair  
United States



**Giorgio Scagliotti**  
IASLC Past-President  
Italy



**Dave Mesko**  
Secretary and IASLC CEO  
United States



**Lauren Fisher**  
Member  
United States



**\$6 MILLION**  
has been given to  
**LUNG CANCER RESEARCH,**  
and that number is on the rise!

# 2020 Donors

## \$200,000

Fred R. Hirsch

---

## \$5,000

David and Diane Gandara  
Li Xu

---

## \$2,500-\$4,999

Ray and Hilda Osarogiagbon

---

## \$1,000-\$2,499

AnnMarie Priest  
David Carbone  
David Spigel  
Gregory and Martha Raber  
Gregory P Galanos  
Paul A. Bunn, Jr.  
William Pao

---

## \$500-\$999

Alain Charles Borczuk  
Dave Mesko  
Heather Wakelee  
Julie Brahmer  
Lauren K. Fisher  
Martin Edelman  
Michael J Boyer  
Paul Van Schil  
Robert Pirker  
Roy S Herbst  
Skaidrius Miliauskas  
Suresh Ramalingam  
Xueming Qian

---

## \$200-\$499

Alfredo Lopez  
Charles Rudin  
Corey Langer  
David Ball  
David James Group  
David S. Gierada  
Eric Bernicker

George A. Eapen  
Gregory M.M. Videtic  
Hossein Borghaei  
Jeannette Hood  
Junichi Shimizu  
Kazuhiko Shibata  
Keunchil Park  
Kristin Richeimer  
Luka Brcic  
Maria Amelia Brilhante Almeida  
Maria Catherine Pietanza  
Michael Jones  
Ming Sound Tsao  
Misako Nagasaka  
National Storage Affiliates  
Quincy Chu  
Rui Haddad  
Stephen Graziano  
Stephen Lam  
Susie Grant Owen  
The David D Ring Jr Family

---

## \$100-\$199

Alejandro Calvo  
André de Fusco  
Andrea Borondy-Kitts  
Angela Takano  
Anna Tomiak  
Anne Marie Robertson  
Antoinette Wozniak  
Art Mallette  
Betty Tong  
Bruce Dunbar  
Camille Nizet  
Charles Baum  
Christian Couture  
Cristina Fernández  
Daphna Gelblum  
Douglas Arenberg  
Ebenezer Kio  
Edgardo Santos  
Eric Vallieres  
Erik Thunnissen  
Etsuo Fujita  
Francisco Orlandi Jorquera  
Gabrielle Goodman

Giannis Mountzios  
Giovanni L Carboni  
Heidi Nafman-Onda  
Hiromasa Yamamoto  
Hongxu Liu  
Hua Cheng  
Iman Abdalla  
Jacek Kowalski  
Jacques Tabacof  
James R. Jett  
Jason Porter  
Javier Montoro  
Jennifer Wing  
Jiichiro Sasaki  
Jill Forrest  
Jo Monsen  
John & Holly Bohman  
John Doll  
Joy Curzio  
Justin, Krystina, & Kameron Mackowiak  
Karen Reckamp  
Keith Cengel  
Ken Uchibori  
Krassimir Koynov  
Krishna Mohan Mallavarapu  
Leora Horn  
Luis E. Raez  
Luis Gomez Wolff  
Makenzi Evangelist  
Marcia Horn  
Mari Mino-Kenudson  
Marilyn Ramey  
Markus Tiemann  
Mary Jo Fidler  
Masahiro Tsuboi  
Matthew Steliga  
Michael Lanuti  
Michael Rabin  
Minako Sumi  
Munther I. Ajlouni  
Neal Ready  
Paul Walker  
Peggy Dennis  
Philip Bonomi  
Philippe Joubert  
Rubi Khaw Li  
Satoshi Hara

Satoshi Muto  
Sergio Sanchez  
Sergio Santillana  
Shirish Gadgeel  
Stephen Veach  
Sukhmani Padda  
Takahisa Yamazaki  
Takashi Suzuki  
Takuya Aoki  
Terufumi Kato  
Tetsuya Mitsudomi  
Tom John  
Turja Chakrabarti  
Umberto Malapel  
William Walsh  
Yaron Shargall

---

## \$50-99

Aki Katarina Kobayashi  
Andy Saylor  
Angela De Palma  
Apurna Jegannathen  
Bihong Zhao  
Calvin Sze Hang Ng  
Carla Azevedo  
Carla Weenink  
Carlo Genova  
Carolyn Presley  
Choon-Taek Lee  
Clarissa Mathias  
Craig Underhill  
David Barnes  
Denise Aberle  
Diane Colton  
Don Siegel  
Donald and Susan Mackowiak  
Dong Kwan Kim  
Dwight H Owen  
Eeva-maija Nieminen  
Eldsamira Mascarenhas  
Elisabeth Brambilla  
Eugene & Debra Novello  
Fall River Employee Benefits  
Ferdinando Cerciello  
Fiorella Calabrese  
Florence Siu Ting Mok

---

Francoise Galateau Sallé  
Frank Sierawski  
Goetz Kloecker  
Hillary Barbour  
Hirotooshi Hoshiyama  
Honey Sarita Abarquez  
Isac Itzhak Schnirer  
J. Marie Suga  
Jairo Lewgoy  
Jonathon Herbst  
Josh & Rachel Shader  
Kandeean Thuraisingam  
Karen Kane Mcdonnell  
Karlos Noel Rojas Aleta  
Kathy Doherty  
Kelly Graham-Miele  
Kevin Chua  
Leah Klein  
Leah Hamill  
Louise Burke  
Lucia Viola  
Lucianno H P Santos  
Maria Belen Tamayo  
Maria Werner-Wasik  
Marjan Hertoghs  
Martin Reck  
Mary Nave  
Mary Todd  
Masahiro Fukuoka  
Matthew Gubens  
Maya Khalil  
Melanie Janning  
Melina Marmarelis  
Mitchell Magee  
Nancy Cohen  
Naseer Ahmed  
Nico Van Zandwijk  
Paolo Bironzo  
Paul Wheatley-Price  
Peter Briggs  
Peter Illei  
Petruccio Abrantes Sarmento  
Pierre Onda  
Renaud Whitton  
Rie Nakahara  
Rob Stirling  
Robert A. Kratzke



Rudolf Van Puijenbroek  
Sarah Khan  
Sheila Ross  
Shirley Carr  
Soe Aung  
Stacy Gray  
Stephen Liu  
Susan Tredway  
Tessa Baxter  
The e.Y. Initiatives  
Victor Manuel Rojas Gonzales  
Yasushi Yatabe  
Yidan Qin  
Yi-Long Wu  
Yoon-la Choi

---

## UP TO \$49

Alexandra Rice  
Alfredo Aguilar Cartagena  
Allison Gittens  
Amy Moore  
Ana Velazquez Manana  
Andie and Arnie Allen  
Andrea Riccardo Filippi  
Andrzej Milewski  
Andrzej Tysarowski  
Angela Yates  
Angus Pratt  
Anne Traynor  
Ashutosh Sachdeva  
Asrar Alahmadi  
Asuka Okada  
Aurora Obrate  
Avia Nitithamkosol  
Balu Krishna Sasidharan  
Barbara Lafayette Viana Da Luz  
Biagio Ricciuti  
Bibhusal Thapa  
Boris Merckx  
Buge Oz  
Caitlin Enright  
Carlos Alberto Ronquillo Carreon  
Carlos H Barrios  
Catarina Santos  
Charles Shelton  
Cheryl & Carly Esparza

Chihpeng Chang  
Cindy Hansen Bradfield  
Clarissa Baldotto  
Danilo Giffoni  
David Felix Heigener  
David Stewart  
Debbie Pickworth  
Deborah Oles  
Deborah Pach  
Deidre Morgan  
Dennis Kwok Chuen Leung  
Diana Penha  
Diane Legg  
Didik Heriyanto  
Dr. and Mrs. Russell Nusynowitz  
Edwin Javier Crespo Martinez  
Edyta Maria Urbanska  
Ehud Walter  
Elizabeth Hassen  
Eunjue Yi  
Flo Leibin  
Florian Fuchs  
Francisco Suarez  
Froylan Lopez  
Fumiaki Takatsu  
Gerard J Fitzmaurice  
Giorgio Masetti-zannini  
Giovanni Selvaggi  
Go Saito  
Gustavo Almeida  
Gustavo Zerwes  
Heae Surng Park  
Helano Freitas  
Hisao Asamura  
Hsingwu Chen  
Huw Ricketts  
Hyun-Kyung Lee  
Hyun-Seock Shin  
Ina Nordman  
Irina Veytsman  
Iuri Santana  
Jacob Sands  
Jacquelyn E Nixon  
Jad Abbas  
Jaime Enrique Montes Gil  
James Huang  
Janna Berg

Jeff Edelson  
Jennifer Wheeley  
Jeremy L Pautu  
Jesus Carranza Sarmina  
Jill Feldman  
Jing Zhang  
Jiro Kawashima  
Joana Espiga De Macedo  
John Sauer  
John Young  
Jose Clavero  
Joseph Whitlark  
Judi Van Diessen  
Julia (Brewer) Umberger  
Julia Roeper  
Junichi Soh  
Kang-Hao (Kenny) Lu  
Kaoru Kubota  
Karen Liguatan  
Kathy Gately  
Kazumasa Noda  
Kazumi Nishino  
Ken Masuda  
Kevin Nicholas Franks  
Kimberly Rohan  
Kimiko Saito-Shizuku  
Kristi Kruusmaa  
Kristin Ito  
Laetitia Mauti  
Leonardo Brand Rodrigues  
Levent Dalar  
Li Li  
Liliana Mocanu  
Lindsay Thompson  
Lisa Lardizabal  
Lorenzo Gerald Maco Chavez  
Lori McDermott  
Lowell L Hart  
Luciana Castro  
Luigi Ventura  
Luis Zambrano Garcia  
Lukman Tijani  
Manuel Villa Sanchez  
Marcelo Corassa  
Maria Teresa Tsukazan  
Marion James  
Mary V. Macneil

Maryann Bradley  
Masaya Yotsukura  
Mattia Boeri  
Maurizio V. Infante  
Mauro M Zamboni  
Megan Baumgart  
Mélissa Audet  
Melissa Crouse  
Miguel Munoz  
Mikhail Ter-Ovanesov  
Mina Zhang  
Mircea Dediu  
Moises Velez  
Mor Moskovitz  
Motoharu Hamatake  
Motohiro Yamashita  
Myriam Bouchard  
Nan Wu  
Naoko Aragane  
Naomi Kariuki  
Nelson Ang  
Nguyen Son Lam  
Niccolò Daddi  
Nicholas Faris  
Nina Helbekkmo  
Niu Xiaomin  
Nor Salmah Bakar  
Oleg Kshivets  
Padma Sundar  
Paige Black  
Pascal Besman  
Pasquale Sansone  
Paulina Edith González Cisneros  
Pek Koh  
Penelope Araujo  
Pingli Wang  
Raquel Ribeiro  
Reginald Munden  
Rex Michael Santiago  
Riad Amin Abdeljalil  
Ryan Gentzler  
Ryuji Hayashi  
Sanghyuk Song  
Santiago Cabezas-Camarero  
Sarah Wang  
Sebahat Ocak  
Seong Hoon Yoon

Sergio Andrés Mejía Espinosa  
Shigeru Nakane  
Simon Ekman  
Simonetta Mocci  
Souheil Boubia  
Stephanie Cervantes  
Steve Vu  
Sukhinder Atkar-khattra  
Sukru Dilege  
Susan Scott  
Sylvie Gaudet  
Takayuki Takahama  
Tejas Patil  
Thadchawadee Wejrungsikul  
Thomas Sturm  
Tiffini Joseph  
Tindara Franchina  
Tirrell Johnson  
Tomohide Tamura  
Toni Enright  
Umit Tappan  
Victor Rojas Gonzales  
Vilde Drageset Haakensen  
Wasiu Majaro  
Wei Dai  
Wilfried E.E. Eberhardt  
William Nassib William Jr.  
Wilma Smit  
Windfield Tan  
Xiao Hu  
Xiao Li  
Xingzhe Li  
Yanyun Gao  
Yeon Wook Kim  
Yoon Choi  
Yuanqiang Zhang  
Yukihiko Yoshida  
Yukti Choudhury  
Zhengfei Zhu  
Zhibo Tan

# IASLC BOARD OF DIRECTORS

## OFFICERS



**Tetsuya Mitsudomi**  
President  
Japan



**Heather Wakelee**  
President-Elect  
United States



**Giorgio Scagliotti**  
Past-President  
Italy



**Suresh Ramalingam**  
Treasurer  
United States



**Enriqueta Felip**  
Secretary  
Spain



**Dave Mesko**  
Chief Executive Officer  
United States

## MEMBERS



**Andrea Bezjak**  
Canada



**Julie Brahma**  
United States



**Anne Fraser**  
New Zealand



**Roy Herbst**  
United States



**Clarissa Mathias**  
Brazil



**Yuko Nakayama**  
Japan



**Masayuki Noguchi**  
Japan



**Nir Peled**  
Israel



**Erik Thunnissen**  
The Netherlands



**Paul Van Schil**  
Belgium



**James Yang**  
Taiwan



**Caicun Zhou**  
China

# IASLC STAFF



**Dave Mesko**  
Chief Executive Officer



**AnnMarie Priest**  
Chief Development  
Officer and Executive  
Director, ILC  
Foundation



**Kristin Richeimer**  
Chief Experience  
Officer



**John Skadow**  
Chief Financial  
Officer



**Tessa Baxter**  
Foundation  
Coordinator



**Kirsten Black**  
Educational Programs  
Manager



**Becky Bunn**  
Senior Advisor,  
Scientific Relations



**Casey Connolly**  
Scientific Affairs  
Coordinator



**Tammy Curry**  
Administrative  
Assistant



**Jill Daigneault**  
Program Manager



**Beth Dobos**  
Web Content  
Administrator



**Kathy Doherty**  
Director, Human Resources



**Brianda Duarte**  
Scientific Affairs  
Coordinator



**Ken Harrell**  
Member Records  
Administrator

## STAFF CONTINUED




**Kristin Ito**  
Associate Director,  
ILC Foundation and  
Patient Advocacy



**Stephanie Lenhart**  
Accounting Manager



**Sara Lindsey**  
Administrative  
Assistant



**Katie Maher**  
Member Experience  
Coordinator



**Jan Mazotti**  
Associate Director,  
Communications  
and Marketing



**Abigail Metzger**  
Corporate Relations  
Coordinator



**Karen Muth**  
Executive Assistant  
and Board Liaison



**Anne Orban**  
Marketing  
Coordinator



**Aubrey Shoe**  
CME and Education  
Coordinator



**Jeanette Stensgaard**  
Conference Planning  
Manager



**Mary Todd**  
Managing Editor,  
JTO & JTO CRR



**Jennifer Vitek**  
Program  
Development  
Coordinator



**Kelsey Wood**  
Associate Director,  
Member Experience



**Murry Wynes**  
Senior Advisor,  
Scientific Affairs



**Kexin Yu**  
Accountant

CONQUERING THORACIC CANCERS WORLDWIDE



CONQUERING THORACIC CANCERS WORLDWIDE



IASLC



INTERNATIONAL  
ASSOCIATION  
FOR THE STUDY  
OF LUNG CANCER

999 17th Street, Suite 200 | Denver, Colorado 80202 USA | [www.IASLC.org](http://www.IASLC.org)